Currency effects and rabeprazole's weakness hold back Eisai
This article was originally published in Scrip
Executive Summary
Total net sales at Eisai in the year to 31 March rose by a modest 3% to ¥803.2 billion ($8.73 billion), constrained by the stronger yen and declining US sales of the proton pump inhibitor Aciphex (rabeprazole).